Instagram Outage Disrupts Thousands of U.S. Users 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
IRVINE, Calif., Aug. 01, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Roche Holding AG (“Roche Holding” or the “Company”) (Other OTC:RHHBY). Investors who purchased or otherwise acquired Roche Holding shares from March 2, 2017 through June 5, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm before the August 7, 2017 lead plaintiff motion deadline.
If you purchased shares of Roche Holding during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.
According to the lawsuit, during the Class Period, Roche Holding issued materially false and misleading statements and/or failed to disclose material information, specifically that the combination of the Company’s breast cancer drug, Perjeta, and its older treatment, Herceptin, is only marginally more effective than Herceptin alone in preventing breast cancer, and has a higher rate of side effects. Following this news, Roche Holding’s stock price fell materially, which harmed investors according to the Complaint.
If you want to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].
This press release may be considered Attorney Advertising in certain jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
